Phosphorus magnetic resonance spectroscopy studies in schizophrenia.

Phosphorus magnetic resonance spectroscopy ((31)P MRS) allows in vivo quantification of phosphorus metabolites that are considered to be related to membrane turnover and energy metabolism. In schizophrenia (SZ), (31)P MRS studies found several abnormalities in different brain regions suggesting that alterations in these pathways may be contributing to the pathophysiology. In this paper, we systematically reviewed the (31)P MRS studies in SZ published to date by taking patient characteristics, medication status and brain regions into account. Publications written in English were searched on http://www.ncbi.nlm.nih.gov/pubmed/, by using the keywords 'phosphomonoester', 'phosphodiester', 'ATP', 'phosphocreatine', 'phosphocholine', 'phosphoethanolamine','glycerophosphocholine', 'glycerophosphoethanolamine', 'pH', 'schizophrenia', and 'MRS'. Studies that measured (31)P metabolites in SZ patients were included. This search identified 52 studies. Reduced PME and elevated PDE reported in earlier studies were not replicated in several subsequent studies. One relatively consistent pattern was a decrease in PDE in chronic patients in the subcortical structures. There were no consistent patterns for the comparison of energy related phosphorus metabolites between patients and controls. Also, no consistent pattern emerged in studies seeking relationship between (31)P metabolites and antipsychotic use and other clinical variables. Despite emerging patterns, methodological heterogeneities and shortcomings in this literature likely obscure consistent patterns among studies. We conclude with recommendations to improve study designs and (31)P MRS methods in future studies. We also stress the significance of probing into the dynamic changes in energy metabolism, as this approach reveals abnormalities that are not visible to steady-state measurements.

[1]  P. Williamson,et al.  Longitudinal 4.0 Tesla 31P magnetic resonance spectroscopy changes in the anterior cingulate and left thalamus in first episode schizophrenia , 2009, Psychiatry Research: Neuroimaging.

[2]  K Ugurbil,et al.  Increase of creatine kinase activity in the visual cortex of human brain during visual stimulation: A 31p NMR magnetization transfer study , 1997, Magnetic resonance in medicine.

[3]  J. Reichenbach,et al.  Effects of olanzapine on 31P MRS metabolic markers in schizophrenia , 2013, Human psychopharmacology.

[4]  T. Inubushi,et al.  Correlations of phosphomonoesters measured by phosphorus-31 magnetic resonance spectroscopy in the frontal lobes and negative symptoms in schizophrenia , 1994, Psychiatry Research: Neuroimaging.

[5]  H. Sauer,et al.  Do neuroleptics alter the cerebral intracellular pH value in schizophrenics?—a 31P-MRS study on three different patient groups , 2002, Psychiatry Research: Neuroimaging.

[6]  W. Kaiser,et al.  31P magnetic resonance spectroscopy in the dorsolateral prefrontal cortex of schizophrenics with a volume selective technique—preliminary findings , 1997, Biological Psychiatry.

[7]  B. Holub Altered phospholipid metabolism in thrombin-stimulated human platelets. , 1984, Canadian journal of biochemistry and cell biology = Revue canadienne de biochimie et biologie cellulaire.

[8]  H. Fukuzako,et al.  Phosphorus magnetic resonance spectroscopy in schizophrenia: Correlation between membrane phospholipid metabolism in the temporal lobe and positive symptoms , 1996, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[9]  M. Krams,et al.  Impaired mitochondrial function in psychiatric disorders , 2012, Nature Reviews Neuroscience.

[10]  A. Heerschap,et al.  31P Magnetic resonance spectroscopic imaging with polarisation transfer of phosphomono‐ and diesters at 3 T in the human brain: relation with age and spatial differences , 2010, NMR in biomedicine.

[11]  T. Inubushi,et al.  Lateralized abnormality of high-energy phosphate and bilateral reduction of phosphomonoester measured by phosphorus-31 magnetic resonance spectroscopy of the frontal lobes in schizophrenia , 1995, Psychiatry Research: Neuroimaging.

[12]  W. Kaiser,et al.  Decreased energy demanding processes in the frontal lobes of schizophrenics due to neuroleptics? A 31P-magneto-resonance spectroscopic study , 1997, Psychiatry Research: Neuroimaging.

[13]  B. Weschke,et al.  31Phosphorus Magnetic Resonance Spectroscopy in Late-Onset Tay-Sachs Disease , 2001, Journal of child neurology.

[14]  T. Inubushi,et al.  Frontal lobe membrane phospholipid metabolism and ventricle to brain ratio in schizophrenia: preliminary 31P-MRS and CT studies , 2000, European Archives of Psychiatry and Clinical Neuroscience.

[15]  D. Laifenfeld,et al.  Mitochondria, synaptic plasticity, and schizophrenia. , 2004, International review of neurobiology.

[16]  Ewald Moser,et al.  7‐T MR—from research to clinical applications? , 2012, NMR in biomedicine.

[17]  Ravi S. Menon,et al.  Grey and white matter differences in brain energy metabolism in first episode schizophrenia: 31P-MRS chemical shift imaging at 4 Tesla , 2006, Psychiatry Research: Neuroimaging.

[18]  M. Keshavan,et al.  Basal ganglia high-energy phosphate metabolism in neuroleptic-naive patients with schizophrenia: a 31-phosphorus magnetic resonance spectroscopic study. , 2004, The American journal of psychiatry.

[19]  Increase of phosphodiesters during neuroleptic treatment of schizophrenics: a longitudinal 31P-magnetic resonance spectroscopic study , 1999, Biological Psychiatry.

[20]  T. Asakura,et al.  Study of chronic schizophrenics using 31P magnetic resonance chemical shift imaging , 1992, Acta psychiatrica Scandinavica.

[21]  B. Puri,et al.  Cerebral metabolism in male patients with schizophrenia who have seriously and dangerously violently offended: a 31P magnetic resonance spectroscopy study. , 2004, Prostaglandins, leukotrienes, and essential fatty acids.

[22]  H. Sauer,et al.  Antipsychotic drug effects on left prefrontal phospholipid metabolism: A follow-up 31P-2D-CSI study of haloperidol and risperidone in acutely ill chronic schizophrenia patients , 2012, Schizophrenia Research.

[23]  Heinrich Sauer,et al.  31Phosphorus magnetic resonance spectroscopy of the dorsolateral prefrontal region in schizophrenics—a study including 50 patients and 36 controls , 1998, Biological Psychiatry.

[24]  P. Williamson,et al.  Membrane phospholipid metabolism and schizophrenia: an in vivo 31P-MR spectroscopy study , 1994, Schizophrenia Research.

[25]  G. Fein,et al.  Asymmetry of temporal lobe phosphorous metabolism in schizophrenia: A 31Phosphorous magnetic resonance spectroscopic imaging study , 1995, Biological Psychiatry.

[26]  M. Keshavan,et al.  Frontal lobe metabolism and cerebral morphology in schizophrenia: 31P MRS and MRI studies , 1993, Schizophrenia Research.

[27]  J. Lieberman,et al.  Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. , 1994, The American journal of psychiatry.

[28]  H. Fukuzako,et al.  31P magnetic resonance spectroscopy of the medial temporal lobe of schizophrenic patients with neuroleptic-resistant marked positive symptoms , 2005, European Archives of Psychiatry and Clinical Neuroscience.

[29]  Dennis Velakoulis,et al.  Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. , 2005, Schizophrenia bulletin.

[30]  M. Keshavan,et al.  Developmental reflexes and 31P Magnetic Resonance Spectroscopy of basal ganglia in antipsychotic-naive schizophrenia , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[31]  G. Fein,et al.  31Phosphorus magnetic resonance spectroscopy of the frontal and parietal lobes in chronic schizophrenia , 1994, Biological Psychiatry.

[32]  B. Cohen,et al.  In vivo evidence for cerebral bioenergetic abnormalities in schizophrenia measured using 31P magnetization transfer spectroscopy. , 2014, JAMA psychiatry.

[33]  P. Williamson,et al.  An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. , 1995, Archives of general psychiatry.

[34]  H. Sauer,et al.  Reduced phosphodiesters and high-energy phosphates in the frontal lobe of schizophrenic patients: a 31P chemical shift spectroscopic-imaging study , 2000, Biological Psychiatry.

[35]  J. Yacubian,et al.  31P-spectroscopy of frontal lobe in schizophrenia: alterations in phospholipid and high-energy phosphate metabolism , 2002, Schizophrenia Research.

[36]  G. Fein,et al.  31Phosphorus magnetic resonance spectroscopy of the temporal lobes in schizophrenia , 1992, Biological Psychiatry.

[37]  D Ongur,et al.  Abnormal high-energy phosphate molecule metabolism during regional brain activation in patients with bipolar disorder , 2015, Molecular Psychiatry.

[38]  J. Waddington,et al.  Initial investigation of the left temporoparietal region in schizophrenia by 31P magnetic resonance spectroscopy , 1991, Biological Psychiatry.

[39]  M. Keshavan,et al.  Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. , 1991, Archives of general psychiatry.

[40]  Ravi S. Menon,et al.  Region-specific changes in phospholipid metabolism in chronic, medicated schizophrenia , 2002, British Journal of Psychiatry.

[41]  Timm Rosburg,et al.  Metabolic mapping using 2D 31P-MR spectroscopy reveals frontal and thalamic metabolic abnormalities in schizophrenia , 2007, NeuroImage.

[42]  S. Bluml,et al.  Quantitative proton-decoupled 31P MRS of the schizophrenic brain in vivo. , 1999, Journal of computer assisted tomography.

[43]  Magnetic resonance imaging volumetric and phosphorus 31 magnetic resonance spectroscopy measurements in schizophrenia. , 1997, Journal of psychiatry & neuroscience : JPN.

[44]  M Takigawa,et al.  Changes in levels of phosphorus metabolites in temporal lobes of drug-naive schizophrenic patients. , 1999, The American journal of psychiatry.

[45]  Ravi S. Menon,et al.  Focal changes in brain energy and phospholipid metabolism in first-episode schizophrenia , 2004, British Journal of Psychiatry.

[46]  Ann K. Shinn,et al.  Gray matter volume in schizophrenia and bipolar disorder with psychotic features , 2012, Schizophrenia Research.

[47]  M. Keshavan,et al.  MRI volumetric and 31P MRS metabolic correlates of caudate nucleus in antipsychotic‐naïve schizophrenia , 2006, Acta psychiatrica Scandinavica.

[48]  Peter Boesiger,et al.  Assessment of absolute metabolite concentrations in human tissue by 31P MRS in vivo. Part I: Cerebrum, cerebellum, cerebral gray and white matter , 1994, Magnetic resonance in medicine.

[49]  P. Williamson,et al.  A 1H-decoupled 31P chemical shift imaging study of medicated schizophrenic patients and healthy controls , 1999, Biological Psychiatry.

[50]  H. Fukuzako,et al.  Haloperidol Improves Membrane Phospholipid Abnormalities in Temporal Lobes of Schizophrenic Patients , 1999, Neuropsychopharmacology.

[51]  C. Pantelis,et al.  Implications of Lipid Biology for the Pathogenesis of Schizophrenia , 2002, The Australian and New Zealand journal of psychiatry.

[52]  T. Inubushi,et al.  Multiple regression analysis of relationship between frontal lobe phosphorus metabolism and clinical symptoms in patients with schizophrenia , 1997, Psychiatry Research: Neuroimaging.

[53]  A. Meyer-Lindenberg,et al.  Altered phospholipid metabolism in schizophrenia: A phosphorus 31 nuclear magnetic resonance spectroscopy study , 2013, Psychiatry Research: Neuroimaging.

[54]  Truman R. Brown,et al.  In Vivo Measurement of Phosphorous Markers of Disease , 2004, Disease markers.

[55]  J. Reichenbach,et al.  Superior temporal metabolic changes related to auditory hallucinations: a 31P-MR spectroscopy study in antipsychotic-free schizophrenia patients , 2013, Brain Structure and Function.

[56]  H. Fukuzako Neurochemical Investigation of the Schizophrenic Brain by in Vivo Phosphorus Magnetic Resonance Spectroscopy , 2001, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[57]  P. Williamson,et al.  Progressive membrane phospholipid changes in first episode schizophrenia with high field magnetic resonance spectroscopy , 2012, Psychiatry Research: Neuroimaging.

[58]  M. Keshavan,et al.  High energy phosphate abnormalities normalize after antipsychotic treatment in schizophrenia: A longitudinal 31P MRS study of basal ganglia , 2010, Psychiatry Research: Neuroimaging.

[59]  G. Fein,et al.  Basal ganglia phosphorous metabolism in chronic schizophrenia. , 1995, The American journal of psychiatry.

[60]  Matcheri S Keshavan,et al.  Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings–part I , 2000, Biological Psychiatry.

[61]  M. Keshavan,et al.  Membrane phospholipid abnormalities of basal ganglia in never-treated schizophrenia a 31P magnetic resonance spectroscopy study , 2003, Biological Psychiatry.

[62]  D. Kupfer,et al.  Biological correlates of slow wave sleep deficits in functional psychoses: 31P-magnetic resonance spectroscopy , 1995, Psychiatry Research.

[63]  Ravi S. Menon,et al.  Comparative study of proton and phosphorus magnetic resonance spectroscopy in schizophrenia at 4 Tesla , 2004, Psychiatry Research: Neuroimaging.

[64]  P. Williamson,et al.  Localized phosphorus 31 magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls. , 1991, Archives of general psychiatry.

[65]  Takashi Ogino,et al.  In vivo31P NMR spectroscopy shows an increase in glycerophosphorylcholine concentration without alterations in mitochondrial function in the prefrontal cortex of medicated schizophrenic patients at rest , 2004, The European journal of neuroscience.

[66]  H. Volz,et al.  High-energy phosphates in the frontal lobe correlate with Wisconsin Card Sort Test performance in controls, not in schizophrenics: a 31phosphorus magnetic resonance spectroscopic and neuropsychological investigation , 1998, Schizophrenia Research.